Oligonucleotide Synthesis Market Valued at US$5.3 Billion in 2025, Set for 14.2% CAGR Growth - Persistence Market Research

The global oligonucleotide synthesis market is entering a transformative phase, fueled by the growing demand for RNA- and DNA-based therapeutics, advanced diagnostic tools, and next-generation research technologies. Valued at US$5.3 billion in 2025, the market is projected to reach US$13.5 billion by 2032, expanding at an impressive CAGR of 14.2%. Oligonucleotides, short DNA or RNA molecules typically composed of 20-30 nucleotides, have become indispensable in the development of targeted therapies, gene modulation technologies, and precision diagnostics. Their role in antisense oligonucleotide (ASO) therapy, which silences harmful gene expression, underscores their growing clinical relevance across oncology, rare genetic disorders, and infectious diseases.

The market's rapid expansion is being driven by multiple factors, including rising R&D investment in synthetic biology, expanding pipelines of oligonucleotide-based drugs, and robust adoption in PCR, sequencing, gene editing, and molecular diagnostics. Among product categories, custom-synthesized oligonucleotides dominate due to their versatility across therapeutic and research applications, accounting for over half of global revenues. Geographically, North America remains the leading region with a projected 42.1% share in 2025, supported by strong regulatory frameworks, advanced manufacturing infrastructure, and early adoption of genomic medicine. Meanwhile, Asia Pacific stands as the fastest-growing market, reflecting increased investment in CDMO and CRDO capabilities, a surge in biotech startups, and government-backed initiatives promoting nucleic acid therapeutics.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/3296

Key Highlights from the Report

• The global oligonucleotide synthesis market is expected to reach US$13.5 billion by 2032, growing at a CAGR of 14.2%.
• North America leads the market with a 42% share in 2025, supported by strong regulatory and R&D ecosystems.
• Asia Pacific is the fastest-growing region due to expanding biomanufacturing and RNA therapeutic innovation.
• Custom oligonucleotides dominate, capturing 58.2% of market share, driven by personalized medicine and advanced research.
• Over 20 oligonucleotide-based drugs have received global regulatory approval as of early 2025.
• Market players are investing in automation, high-throughput synthesis, and sustainable manufacturing to scale production.

Market Segmentation

The oligonucleotide synthesis market can be segmented by product type, oligonucleotide type, and application, each playing a critical role in shaping industry trends and future opportunities.

Product Type Insights

Oligonucleotides themselves remain the core revenue-generating product, representing approximately 45.7% of the market in 2025. These molecules underpin a wide range of applications-from gene modulation and RNA interference to molecular diagnostics and therapeutic design. Their importance is magnified by the growing prevalence of genetic disorders and the expanding use of nucleic acid-based vaccines. Supporting products such as reagents, synthesis equipment, and purification tools complement the market by enhancing throughput and accuracy in synthesis workflows.

Oligonucleotide Type Insights

Within the market, custom-synthesized oligonucleotides account for the dominant 58.2% share in 2025. These tailor-made sequences are integral to applications in gene editing, synthetic biology, and precision therapeutics. Custom synthesis allows for high specificity and flexibility, addressing unique genetic targets or experimental requirements. As biopharma and academic collaborations expand, the demand for customized oligos continues to grow, particularly within RNA interference (RNAi) and CRISPR-based applications.

Application Insights

By application, therapeutic oligonucleotides hold the largest market share of 42.8% in 2025, driven by rapid advancements in antisense, siRNA, and mRNA technologies. These molecules are used to modulate gene expression and treat diseases previously deemed untreatable. The first FDA-approved oligonucleotide therapy emerged in 2017, marking a pivotal shift in molecular medicine. Since then, over 20 such drugs have gained approval worldwide. Beyond therapy, research and diagnostic applications continue to expand, particularly in forensic testing, clinical diagnostics, and synthetic biology, collectively strengthening the market's long-term trajectory.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/oligonucleotide-synthesis-market.asp

Regional Insights

North America

North America leads the global oligonucleotide synthesis market, projected to account for over 42% of global revenues by 2025. The region's dominance is reinforced by its well-established Good Manufacturing Practice (GMP) facilities, high R&D intensity, and favorable regulatory environment for clinical innovation. The U.S. FDA's proactive approach to individualized antisense oligonucleotide (ASO) therapies-through clear investigational guidelines and expedited approval pathways-has encouraged faster clinical translation. Moreover, initiatives such as the N=1 Collaborative (N1C) exemplify the region's leadership in customized genetic therapy development. With strong pharmaceutical infrastructure and leading biotech clusters, North America remains at the forefront of next-generation oligonucleotide research and commercialization.

Europe

Europe follows as a significant regional hub, accounting for approximately 28.8% of global market share in 2025. The region's focus on collaborative research and translational science has catalyzed innovation in oligonucleotide therapeutics. The ON-TRACT initiative, for instance, unites academic and industrial partners to advance oligonucleotide-based treatments for cancer and chronic diseases. Similarly, the 1 Mutation 1 Medicine (1M1M) platform promotes regulatory frameworks supporting ASO treatments for rare diseases. With a strong emphasis on ethical biotechnological development and sustainability, Europe provides a supportive ecosystem for scaling oligonucleotide production and broadening therapeutic applications.

Asia Pacific

The Asia Pacific market is poised for exceptional growth, with a forecast CAGR of 17.8% through 2032. Rapid expansion in biomanufacturing infrastructure, combined with increasing R&D investments from both domestic and international players, positions the region as a global growth engine. In countries like China, Japan, and South Korea, partnerships between research organizations and industry leaders are advancing nucleic acid therapeutics. The establishment of large-scale cGMP oligo manufacturing facilities-such as the Asahi Kasei Bioprocess and Axolabs partnership-reflects the region's growing emphasis on quality and scalability. Furthermore, licensing deals like Hongene Biotech's collaboration with UMass Chan Medical School highlight Asia Pacific's emergence as a hub for RNA interference, ASO, and CRISPR-based therapies.

Market Drivers

One of the most powerful growth drivers for the oligonucleotide synthesis market is the expanding pipeline of oligonucleotide-based therapeutics. With over 20 approved drugs and hundreds of candidates in development, the field has transitioned from niche research to mainstream biotechnology. Increasing regulatory support and financing-such as AusperBio's US$73 million funding round for hepatitis B and Judo Bio's US$100 million investment in kidney-targeted oligonucleotides-demonstrate strong investor confidence. Technological advancements, including improved delivery systems and high-throughput synthesis, further accelerate clinical adoption. Additionally, the integration of oligonucleotides in diagnostic assays, genetic testing, and personalized medicine continues to drive robust demand across healthcare sectors. The rising prevalence of genetic disorders and infectious diseases, coupled with innovations in RNA-based therapeutics, ensures sustained market momentum.

Market Restraints

Despite strong growth potential, the market faces technological and cost-related challenges that hinder large-scale commercialization. The prevailing phosphoramidite-based solid-phase synthesis method, while effective for shorter sequences, becomes inefficient for longer constructs, resulting in yield loss and higher error rates. The production of siRNA, for instance, involves over 160 complex steps and requires several tons of raw materials to generate a single kilogram of high-purity product-often costing more than US$1 million per kg. Additionally, the industry's reliance on toxic solvents and complex purification processes raises environmental and operational concerns. Although enzymatic synthesis offers promise for cleaner and more selective oligo production, limitations in template compatibility and nucleotide modification currently restrict scalability. These process inefficiencies, combined with stability and delivery challenges for therapeutic oligos, remain critical barriers to mass adoption and cost reduction.

Market Opportunities

The automation and digital transformation of oligonucleotide manufacturing represent major opportunities for market expansion. Automated synthesis systems equipped with Process Analytical Technology (PAT) ensure reproducibility, enhance purity control, and reduce manual intervention, enabling efficient large-scale production. Similarly, the rise of modular biomanufacturing and hybrid batch-solution systems enhances flexibility and cost-efficiency, paving the way for sustainable scale-up. Moreover, as oligonucleotide-based drugs expand into oncology, cardiology, and neurology, the need for affordable, high-volume production continues to grow. Emerging markets, particularly in Asia Pacific, are investing heavily in next-generation RNA and DNA synthesis technologies, while global players explore AI-driven design and predictive analytics to improve accuracy and shorten development timelines. Collectively, these advancements are creating a fertile landscape for innovation and long-term commercial growth.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/3296

Company Insights

The oligonucleotide synthesis market is highly competitive, featuring a mix of established biotechnology firms and emerging innovators focused on expanding synthesis capabilities, improving throughput, and integrating automation.

Key Players in the Market:
• Integrated DNA Technologies, Inc.
• GenScript Biotech Corporation
• Eurofins Scientific SE
• Bioneer Corporation
• Kaneka Corporation (Eurogentec)
• Biolegio B.V.
• Eton Bioscience, Inc.
• IBA GmbH
• Quintara Biosciences
• LGC Biosearch Technologies
• Thermo Fisher Scientific, Inc.
• TriLink BioTechnologies, LLC
• TAG Copenhagen A/S
• PolyGen GmbH
• General Electric Co.
• BioAutomation
• Biolytic Lab Performance Inc.
• Others

Market Segmentation

By Product

Oligonucleotides
Reagents & Consumables
Equipment/Synthesizers

By Oligonucleotide Type

Custom Oligonucleotides
Predesigned Oligonucleotides

By Application

Therapeutic
Diagnostic
Research

By End-user

Pharma & Biopharma Companies
Diagnostic Laboratories
Academic & Research Institutes
CROs/CMOs

By Region

North America
Europe
East Asia
South Asia & Oceania
Latin America
Middle East & Africa

Recent Developments

Oligo Factory (May 2025): Launched low-scale oligo synthesis to support therapeutic and diagnostic development, showcasing its FactorTxTM portfolio at TIDES USA 2025.

Codexis (December 2024): Opened its ECO Synthesis Innovation Lab, focusing on enzymatic oligonucleotide production to deliver GLP-grade materials for preclinical use, marking a major step toward sustainable biomanufacturing.

These strategic initiatives, alongside mergers, acquisitions, and new facility expansions, reflect the market's dynamic evolution and growing global competitiveness.

Conclusion

The oligonucleotide synthesis market is positioned at the intersection of biotechnology, genomics, and precision medicine-an industry transforming the way diseases are diagnosed and treated. With the market projected to grow from US$5.3 billion in 2025 to US$13.5 billion by 2032, driven by a 14.2% CAGR, the sector reflects a profound shift toward RNA- and DNA-based therapeutic innovation. As automation, digitalization, and high-throughput technologies redefine production efficiency, barriers related to cost, scalability, and environmental impact are gradually being addressed.

North America's leadership in regulation and R&D, coupled with Asia Pacific's manufacturing expansion, ensures a geographically diverse and resilient growth landscape. Looking forward, oligonucleotide synthesis will continue to underpin the next generation of gene-based therapies, molecular diagnostics, and precision healthcare, making it one of the most dynamic frontiers in modern biotechnology.

Read More Related Reports:

Wound Antiseptics Market https://www.persistencemarketresearch.com/market-research/wound-antiseptics-market.asp
Ringing Ears Treatment Market https://www.persistencemarketresearch.com/market-research/ringing-ears-treatment-market.asp
Overweight Treatment Market https://www.persistencemarketresearch.com/market-research/overweight-treatment-market.asp
Stroke Rehabilitation Market https://www.persistencemarketresearch.com/market-research/stroke-rehabilitation-market.asp

Contact Us:

Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ, United Kingdom
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.